Endocrine Abstracts

Introduction: Diabetes is increasing its prevalence as an enhancement of treatment options arises and mortality declines. Pancreas transplantation has been postulated as one of them, specifically indicated for cases with end-stage renal failure where kidney transplantation is required besides. It has been analysed whether there is a clinical benefit in terms of quality of life (QoL) in patients undergoing pancreas-kidney transplantation (PKT) compared to dyalisis population or other solid-organ transplantation.

Objective: To determine if PKT has a medium-short term impact in QoL in patients with type 1 diabetes mellitus (T1DM) and end-stage renal disease (group PKT) compared to patients with T1DM without end-stage renal disease and indication for PKT (group no-PKT).

Methods and patients: We analysed data from 40 patients admitted in Hospital Universitario Reina Sofía from 2013 to 2018 for simultaneous PKT. We compared them to a random sample of 40 patients suffering from T1DM under insulin treatment for at least 5 years before the study (group no-PKT). Quality of life was assesed using the 36-Item Short Form Health Survey questionnaire (SF-36). Quality of life data were analysed with Mann-Whitney U Test. Continuous cuantitative variables were compared using Student’s T Test. Data was analysed using SPSS v. 24.

Results: Patients in both groups showed a similar distribution regarding sex and BMI. No-PKT patients were older than PKT receptors (42.9 vs 38.32 years old, statistically significant). T1DM patients not undergoing PKT had an average duration of the disease of 26.37 years and a HbA1c of 7.92% (63.1 mmol/mol). SF-36 showed a favorable statistically significant (P < 0.05) impact of PKT when compared to no-PKT group in general health, bodily pain, social functioning, vitality, mental health and health change scales. There were no differences in physical functioning and emotional role SF-36 scales. We observed worse statistically significant (P < 0.05) results regarding physical role scale in PKT recipients.

Conclusions: 1. In our sample, baseline characteristics of patients undergoing PKT are similar to those described in the literature.

2. PKT has a beneficial overall impact in quality of life in patients suffering from T1DM and end-stage renal failure from our sample. However, there are some aspects were we did not find a beneficial result.

3. More studies with a larger sample and follow-up period, prospective data and comparable control groups should be performed in order to confirm these results.